The CCL2–CCR2 axis is implicated in macrophage recruitment in CTCL lesions, and preclinical studies suggest that CCR2 antagonism can reduce TAM enrichment and may synergize with immune checkpoint blockade in CTCL models [111]. The gene discussed is CCR2; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.